Dyne Therapeutics, Inc. Lease, Cost
Dyne Therapeutics, Inc. (DYN) reported Lease, Cost of $8.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-02
- Dyne Therapeutics, Inc. lease, cost for the quarter ending 2021-12-31 was $6.44M.
- Dyne Therapeutics, Inc. lease, cost for the quarter ending 2021-09-30 was $324.00K.
- Dyne Therapeutics, Inc. lease, cost for the quarter ending 2021-06-30 was $320.00K.
- Dyne Therapeutics, Inc. lease, cost for the quarter ending 2021-03-31 was $304.00K.
- Dyne Therapeutics, Inc. lease, cost for fiscal 2025 was $8.29M, a 7.42% increase from fiscal 2024.
- Dyne Therapeutics, Inc. lease, cost for fiscal 2024 was $7.71M, a 2.24% increase from fiscal 2023.
- Dyne Therapeutics, Inc. lease, cost for fiscal 2023 was $7.54M, a 2.08% increase from fiscal 2022.
- Dyne Therapeutics, Inc. lease, cost for fiscal 2022 was $7.39M, a 0.00% change from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $8.29M 10-K · filed 2026-03-02 | ||||
| 2024-12-31 | $7.71M 10-K · filed 2026-03-02 | ||||
| 2023-12-31 | $7.54M 10-K · filed 2026-03-02 | ||||
| 2022-12-31 | $7.39M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $6.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $6.76M derived: sum of 2 quarters · filed 2024-03-05 | $7.08M derived: sum of 3 quarters · filed 2024-03-05 | $7.39M 10-K · filed 2024-03-05 | $2.70M 10-K · filed 2022-03-10 |
| 2021-09-30 | $324.00K 10-Q · filed 2021-11-04 | $644.00K derived: sum of 2 quarters · filed 2021-11-04 | $950.00K 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | $320.00K 10-Q · filed 2021-08-05 | $625.00K 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $304.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |